118 related articles for article (PubMed ID: 32277010)
1. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in sebaceous carcinomas.
Saliba M; Shaheen M; Hajj RE; Abbas F; Bashir S; Sheikh UN; Mahfouz R; Loya A; Khalifeh I
Cancer Immunol Immunother; 2021 Jul; 70(7):1907-1915. PubMed ID: 33398391
[TBL] [Abstract][Full Text] [Related]
3. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J;
Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
6. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
Chen X; Chen H; Lin R; Li Y; Guo Y; Chen Q; Zhang Y; Cai G; Hu M; Chen G
J Clin Pathol; 2023 Dec; 77(1):61-67. PubMed ID: 36319076
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
Singh L; Singh MK; Kenney MC; Jager MJ; Rizvi MA; Meel R; Lomi N; Bakhshi S; Sen S; Kashyap S
Cancer Immunol Immunother; 2021 May; 70(5):1291-1303. PubMed ID: 33136179
[TBL] [Abstract][Full Text] [Related]
8. Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.
Quan Q; Guo L; Huang L; Liu Z; Guo T; Shen Y; Ding S; Liu C; Cao L
Medicine (Baltimore); 2023 Dec; 102(48):e36323. PubMed ID: 38050283
[TBL] [Abstract][Full Text] [Related]
9. High tumour mutational burden is associated with strong PD-L1 expression, HPV negativity, and worse survival in penile squamous cell carcinoma: an analysis of 165 cases.
Hrudka J; Hojný J; Prouzová Z; Kendall Bártů M; Čapka D; Zavillová N; Matěj R; Waldauf P
Pathology; 2024 Apr; 56(3):357-366. PubMed ID: 38161143
[TBL] [Abstract][Full Text] [Related]
10. Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.
Samiei A; Gjertson DW; Memarzadeh S; Konecny GE; Moatamed NA
Diagn Pathol; 2022 Sep; 17(1):70. PubMed ID: 36104728
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
[TBL] [Abstract][Full Text] [Related]
12. PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Röver LK; Gevensleben H; Dietrich J; Bootz F; Landsberg J; Goltz D; Dietrich D
EBioMedicine; 2018 Feb; 28():97-104. PubMed ID: 29396294
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.
Hirai H; Nakaguro M; Tada Y; Saigusa N; Kawakita D; Honma Y; Kano S; Tsukahara K; Ozawa H; Okada T; Okami K; Yamazaki K; Sato Y; Urano M; Kajiwara M; Utsumi Y; Shimura T; Fushimi C; Shimizu A; Kondo T; Imanishi Y; Sakai A; Sato Y; Togashi T; Hanazawa T; Matsuki T; Yamazaki K; Nagao T
Virchows Arch; 2023 Sep; 483(3):367-379. PubMed ID: 37464232
[TBL] [Abstract][Full Text] [Related]
14. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
[TBL] [Abstract][Full Text] [Related]
15. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
17. Verification of the expression trend and interaction prediction of innate immune cells and immune-checkpoint molecules in the process of oral mucosal carcinogenesis.
Li K; Shi L; Liu L; Wang J; Nie M; Liu X
Hua Xi Kou Qiang Yi Xue Za Zhi; 2024 Apr; 42(2):192-206. PubMed ID: 38597079
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value and immunological role of PD-L1 gene in pan-cancer.
Wang Y; Jiang H; Fu L; Guan L; Yang J; Ren J; Liu F; Li X; Ma X; Li Y; Cai H
BMC Cancer; 2024 Jan; 24(1):20. PubMed ID: 38166842
[TBL] [Abstract][Full Text] [Related]
19. The effect of hypoxia on PD-L1 expression in bladder cancer.
Smith V; Mukherjee D; Lunj S; Choudhury A; Hoskin P; West C; Illidge T
BMC Cancer; 2021 Nov; 21(1):1271. PubMed ID: 34819027
[TBL] [Abstract][Full Text] [Related]
20. CD4
Franken A; Bila M; Mechels A; Kint S; Van Dessel J; Pomella V; Vanuytven S; Philips G; Bricard O; Xiong J; Boeckx B; Hatse S; Van Brussel T; Schepers R; Van Aerde C; Geurs S; Vandecaveye V; Hauben E; Vander Poorten V; Verbandt S; Vandereyken K; Qian J; Tejpar S; Voet T; Clement PM; Lambrechts D
Immunity; 2024 Mar; 57(3):541-558.e7. PubMed ID: 38442708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]